Bristol Paying $2 Bil. For ImClone C225; New Milestone For Inlicensing Deals?
Executive Summary
Bristol-Myers Squibb's $2 bil. investment in ImClone's anti-cancer monoclonal antibody C225 (cetuximab) represents a $500 mil. premium to the company's estimate of the peak annual sales potential for the agent.
You may also be interested in...
GSK Decreases Reliance On Late-Stage Licenses, Citing Strength In R&D
GlaxoSmithKline is reducing its reliance on late-stage in-licensing deals following an R&D restructuring program that has yielded a burgeoning pipeline, CEO J.P. Garnier told analysts
GSK Decreases Reliance On Late-Stage Licenses, Citing Strength In R&D
GlaxoSmithKline is reducing its reliance on late-stage in-licensing deals following an R&D restructuring program that has yielded a burgeoning pipeline, CEO J.P. Garnier told analysts
Pharma Faces Phase III Licensing Drought; Separate R&D “Pools” May Help
Pharmaceutical companies should separate R&D budgets for internal and external deals, Bayer Licensing & Acquisitions Associate Director Ann Kraft suggested